人乳头瘤病毒L2的一种具有保护作用且广泛交叉中和的表位
A protective and broadly cross-neutralizing epitope of human papillomavirus L2.
作者信息
Gambhira Ratish, Karanam Balasubramanyam, Jagu Subhashini, Roberts Jeffrey N, Buck Christopher B, Bossis Ioannis, Alphs Hannah, Culp Timothy, Christensen Neil D, Roden Richard B S
机构信息
Department of Pathology, The Johns Hopkins University, Baltimore, Maryland 21231, USA.
出版信息
J Virol. 2007 Dec;81(24):13927-31. doi: 10.1128/JVI.00936-07. Epub 2007 Oct 10.
Abstract
We generated a monoclonal antibody, RG-1, that binds to highly conserved L2 residues 17 to 36 and neutralizes human papillomavirus 16 (HPV16) and HPV18. Passive immunotherapy with RG-1 was protective in mice. Antiserum to the HPV16 L2 peptide comprising residues 17 to 36 (peptide 17-36) neutralized pseudoviruses HPV5, HPV6, HPV16, HPV 18, HPV31, HPV 45, HPV 52, HPV 58, bovine papillomavirus 1, and HPV11 native virions. Depletion of HPV16 L2 peptide 17-36-reactive antibodies from cross-neutralizing rabbit and human L2-specific sera abolished cross-neutralization and drastically reduced neutralization of the cognate type. This cross-neutralization of diverse HPVs associated with cervical cancer, genital warts, and epidermodysplasia verruciformis suggests the possibility of a broadly protective, peptide-based vaccine.
摘要
我们制备了一种单克隆抗体RG-1，它能与高度保守的L2蛋白第17至36位残基结合，并中和人乳头瘤病毒16型（HPV16）和HPV18。用RG-1进行的被动免疫疗法在小鼠中具有保护作用。针对包含第17至36位残基的HPV16 L2肽（肽17-36）的抗血清可中和假病毒HPV5、HPV6、HPV16、HPV18、HPV31、HPV45、HPV52、HPV58、牛乳头瘤病毒1型以及HPV11天然病毒体。从具有交叉中和作用的兔和人L2特异性血清中去除与HPV16 L2肽17-36反应的抗体，可消除交叉中和作用，并大幅降低同源型别的中和作用。这种与宫颈癌、尖锐湿疣和疣状表皮发育异常相关的多种HPV的交叉中和作用提示了基于肽的广泛保护性疫苗的可能性。
相似文献
1
A protective and broadly cross-neutralizing epitope of human papillomavirus L2.
J Virol. 2007 Dec;81(24):13927-31. doi: 10.1128/JVI.00936-07. Epub 2007 Oct 10.
2
Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Virology. 2007 Feb 20;358(2):266-72. doi: 10.1016/j.virol.2006.08.037. Epub 2006 Sep 28.
3
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.
Virology. 2005 Jul 5;337(2):365-72. doi: 10.1016/j.virol.2005.04.011.
4
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.
Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5850-5. doi: 10.1073/pnas.0800868105. Epub 2008 Apr 14.
5
Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
Antiviral Res. 2019 Jun;166:56-65. doi: 10.1016/j.antiviral.2019.03.012. Epub 2019 Mar 26.
6
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
Vaccine. 2007 Mar 1;25(11):2001-10. doi: 10.1016/j.vaccine.2006.11.049. Epub 2006 Nov 29.
7
Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies.
Vaccine. 2001 Jan 8;19(11-12):1496-502. doi: 10.1016/s0264-410x(00)00367-4.
8
Cross-neutralization potential of native human papillomavirus N-terminal L2 epitopes.
PLoS One. 2011 Feb 8;6(2):e16405. doi: 10.1371/journal.pone.0016405.
9
Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
Vaccine. 2014 Jul 23;32(34):4267-74. doi: 10.1016/j.vaccine.2014.06.054. Epub 2014 Jun 21.
10
Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.
Clin Vaccine Immunol. 2015 Jul;22(7):806-16. doi: 10.1128/CVI.00799-14. Epub 2015 May 13.
引用本文的文献
1
The h4 coil surface region of human papillomavirus type 58 L1 virus-like particle serves as a potential location for presenting the RG1 epitope peptide.
Hum Vaccin Immunother. 2025 Dec;21(1):2477966. doi: 10.1080/21645515.2025.2477966. Epub 2025 Apr 1.
2
Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded.
Infect Agent Cancer. 2025 Mar 10;20(1):16. doi: 10.1186/s13027-025-00643-5.
3
Treatment and Prevention of HPV-Associated Skin Tumors by HPV Vaccination.
Vaccines (Basel). 2024 Dec 20;12(12):1439. doi: 10.3390/vaccines12121439.
4
Glycan-induced structural activation softens the human papillomavirus capsid for entry through reduction of intercapsomere flexibility.
Nat Commun. 2024 Nov 21;15(1):10076. doi: 10.1038/s41467-024-54373-0.
5
Current status and future directions for the development of human papillomavirus vaccines.
Front Immunol. 2024 Jun 25;15:1362770. doi: 10.3389/fimmu.2024.1362770. eCollection 2024.
6
Vaccination with a Human Papillomavirus L2 Multimer Provides Broad Protection against 17 Human Papillomavirus Types in the Mouse Cervicovaginal Challenge Model.
Vaccines (Basel). 2024 Jun 20;12(6):689. doi: 10.3390/vaccines12060689.
7
Arginine-linked HPV-associated E7 displaying bacteria-derived outer membrane vesicles as a potent antigen-specific cancer vaccine.
J Transl Med. 2024 Apr 22;22(1):378. doi: 10.1186/s12967-024-05195-7.
8
Naturally developed HPV16 antibodies and risk of newly detected cervical HPV infection outcomes.
J Med Virol. 2024 Apr;96(4):e29608. doi: 10.1002/jmv.29608.
9
Inter-epitope spacer variation within polytopic L2-based human papillomavirus antigens affects immunogenicity.
NPJ Vaccines. 2024 Feb 24;9(1):44. doi: 10.1038/s41541-024-00832-0.
10
Virus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies.
J Ovarian Res. 2024 Jan 16;17(1):19. doi: 10.1186/s13048-023-01325-9.
本文引用的文献
1
Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Virology. 2007 Feb 20;358(2):266-72. doi: 10.1016/j.virol.2006.08.037. Epub 2006 Sep 28.
2
Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles.
J Virol. 2006 Dec;80(24):12393-7. doi: 10.1128/JVI.01583-06. Epub 2006 Sep 27.
3
How will HPV vaccines affect cervical cancer?
Nat Rev Cancer. 2006 Oct;6(10):753-63. doi: 10.1038/nrc1973.
4
Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection.
J Virol. 2005 Jun;79(11):6723-31. doi: 10.1128/JVI.79.11.6723-6731.2005.
5
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.
Virology. 2005 Jul 5;337(2):365-72. doi: 10.1016/j.virol.2005.04.011.
6
Pathogenesis of human papillomaviruses in differentiating epithelia.
Microbiol Mol Biol Rev. 2004 Jun;68(2):362-72. doi: 10.1128/MMBR.68.2.362-372.2004.
7
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
Clin Cancer Res. 2004 May 1;10(9):2954-61. doi: 10.1158/1078-0432.ccr-03-0703.
8
Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins.
Vaccine. 2004 Jan 26;22(5-6):670-80. doi: 10.1016/j.vaccine.2003.08.037.
9
Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers.
Vaccine. 2003 Oct 1;21(27-30):4256-60. doi: 10.1016/s0264-410x(03)00454-7.
10
Cell surface-binding motifs of L2 that facilitate papillomavirus infection.
J Virol. 2003 Mar;77(6):3531-41. doi: 10.1128/jvi.77.6.3531-3541.2003.
Zotero 插件